# Survival_Analysis_HIV_Mortality
This study analyzes survival outcomes in HIV patients who were intolerant or had failed AZT therapy and were subsequently treated with didanosine (ddI) or zalcitabine (ddC). It uses survival analysis to assess treatment effectiveness, examine the impact of CD4 cell counts on mortality, and identify key factors influencing survival
